Atsena Presents Positive 18-Month Results from Part A of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis

Data ReadoutpositiveATSN-201Positive

AI Analysis

Summary

Atsena announced positive 18-month results from Part A of the Phase 1/2/3 LIGHTHOUSE trial of ATSN-201 for X-linked Retinoschisis, demonstrating a favorable safety profile and durable structural and functional benefits.

Clinical Trial Data

Phase

1/2/3

Primary Endpoint

Met

Outcome Details

18-month results from Part A of LIGHTHOUSE Trial demonstrate favorable safety profile and durable structural and functional benefits

Importance:6/10

Sentiment:

0.75

clinical trial dataophthalmologygene therapyrare disease

Related Companies

$MEHA

Read the original article

Published by GlobeNewswire Clinical Studies on September 30, 2026 8:05 PM

Read Original